Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

2.620 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Affimed Ord Shs

< Previous 1 2 3 Next >
Affimed Reports Third Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the Cantor Global Healthcare Conference 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Second Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed Appoints Shawn M. Leland as Chief Executive Officer
From Affimed N.V.
Via GlobeNewswire
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Reports First Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
From Affimed N.V.
Via GlobeNewswire
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
Affimed Reports 2023 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
From Affimed N.V.
Via GlobeNewswire
Affimed Announces 1-for-10 Reverse Stock Split
From Affimed N.V.
Via GlobeNewswire
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Leadership Change and Organizational Restructuring
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
From Affimed N.V.
Via GlobeNewswire
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
From Affimed N.V.
Via GlobeNewswire
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
From Affimed N.V.
Via GlobeNewswire
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed to Participate in Upcoming Investor Conferences
From Affimed N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.